Trial
NCT02670330
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
Phase IIITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics
Condition
Epidermolysis Bullosa
Intervention
SD-101-6.0 cream
Why stopped
The Sponsor voluntarily recalled SD-101 and terminated the study due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-27